Login / Signup

Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.

Eui Gwon HwangEun-Ae JungJeong-Ju YooSang Gyune KimYoung Seok Kim
Published in: Hepatology international (2023)
TAF continues to worsen lipid profiles including LDL-c, TC, and TG after 6 months of use compared to the other NAs.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • hepatitis b virus
  • fatty acid
  • patient reported outcomes
  • patient reported